Generation of an adenovirus vector lacking E1, E2a, E3, and all of E4 except open reading frame 3

Journal of Virology

Volumn 73, Issue 7, 1999, Pages 6048-6055

  Gorziglia, Mario I ^a   Lapcevich, Claudia ^a   Roy, Soumitra ^a   Kang, Qiang ^a   Kadan, Mike ^a   Wu, Vivian ^a   Pechan, Peter ^a   Kaleko, Mike ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; VIRUS VECTOR;

ADENOVIRUS; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; GENE DELETION; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; GENETIC TRANSFECTION; MOUSE; NONHUMAN; OPEN READING FRAME; PRIORITY JOURNAL; TRANSGENE; VIRUS GENE; VIRUS GENOME;

EID: 0032991720     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.73.7.6048-6055.1999     Document Type: Article

References (45)

1. Amalfitano, A., M. A. Hauser, H. Hu, D. Serra, C. R. Begy, and J. S. Chamberlain. 1998. Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted. J. Virol. 72:926-933.
2. Armentano, D., J. Zabner, C. Sacks, C. C. Sookdeo, M. P. Smith, J. A. St. George, S. C. Wadsworth, A. E. Smith, and R. J. Gregory. 1997. Effect of the E4 region on the persistence of transgene expression from adenovirus vectors. J. Virol. 71:2408-2416.
3. Barr, D., J. Tubb, D. Fergunson, A. Scaria, A. Lieber, C. Wilson, J. Perkin, and M. A. Kay. 1995. Strain related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: comparison between immunocompetent and immunodeficient inbred strains. Gene Ther. 2:151-155.
4. Berkner, K. L. 1988. Development of adenovirus vectors for the expression of heterologous genes. BioTechniques 6:616-629.
5. Bridge, E., and G. Ketner. 1989. Redundant control of adenovirus late gene expression by early region 4. J. Virol. 63:631-638.
6. Brough, D. E., C. Hsu, V. A. Kulesa, G. M. Lee, L. J. Cantolupo, A. Lizonova, and I. Kovesdi. 1997. Activation of transgene expression by early region 4 is responsible for a high level of persistent transgene expression from adenovirus vectors in vivo. J. Virol. 71:9206-9213.
7. Burcin, M. M., G. Schieder, S. Kochaneck, S. Y. Tsai, and B. W. O'Malley. 1999. Adenovirus-mediated regulable target gene expression in vivo. Proc. Natl. Acad. Sci. USA 94:355-360.
8. Carvalho, T., J.-S. Seeler, K. Ohman, P. Jordan, U. Pettersson, G. Akusjarvi, M. Carmo-Fonseca, and A. Dejean. 1995. Targeting of adenovirus E1A and E4orf3 proteins to nuclear matrix-associated PML bodies. J. Cell Biol. 131: 45-56.
9. Dai, Y., E. M. Schwartz, D. Gu, W. W. Zhang, N. Sarvetnick, and I. M. Verma. 1995. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc. Natl. Acad. Sci. USA 92:1401-1405.
10. Dedieu, J. F., E. Vigne, C. Torrent, C. Julien, I. Mahfouz, J. M. Caillaud, N. Aubailly, C. Orsini, J. M. Guillaume, P. Opolon, P. Delaere, M. Perricaudet, and P. Yeh. 1997. Long-term gene delivery into the livers of immunocompetent mice with E1/E4-defective adenoviruses. J. Virol. 71:4626-4637.
11. Dobner, T., N. Horikoshi, S. Rubenwolf, and T. Shenk. 1996. Blockage by adenovirus E4orf6 of transcription activation by the p53 tumor suppressor. Science 272:1470-1473.
12. Doucas, V., A. M. Ishov, A. Romo, H. Juguilon, M. D. Weitzman, R. M. Evans, and G. G. Maul. 1996. Adenovirus replication is coupled with the dynamic properties of the PML nuclear structure. Genes Dev. 10:196-207.
13. Engelhardt, J. F., X. Ye, B. Doranz, and J. M. Wilson. 1994. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc. Natl. Acad. Sci. USA 91:6196-6200.
14. Engelhardt, J. F., L. Litzky, and J. M. Wilson. 1994. Prolonged transgene expression in cotton rat lung with recombinant adenoviruses defective in E2a. Hum. Gene Ther. 5:1217-1229.
15. Fisher, K. J., H. Choi, J. Burda, S.-J. Chen, and J. M. Wilson. 1996. Recombinant adenovirus deleted of all DNA viral genes for gene therapy of cystic fibrosis. Virology 217:11-22.
16. Gao, G. P., Y. Yang, and J. M. Wilson. 1996. Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy. J. Virol. 70:8934-8943.
17. Gorziglia, M. I., M. J. Kadan, S. Yei, J. Lim, G. M. Lee, R. Luthra, and B. C. Trapnell. 1996. Elimination of both E1 and E2a from adenovirus vectors further improves prospects for in vivo human gene therapy. J. Virol. 70: 4173-4178.
18. Graham, F. L., and L. Prevec. 1992. Adenovirus based expression vectors and recombinant vaccines, p. 363-390. In R. W. Ellis (ed.), Vaccines: new approaches to immunological problems. Butterworth-Heinemann, London, United Kingdom.
19. Hanahan, D., and Y. Gluzman. 1984. Rescue of functional replication origins from embedded configurations in a plasmid carrying the adenovirus genome. Mol. Cell. Biol. 4:302-309.
20. Joos, K., C. J. Hildegund, and J. M. Wilson. 1998. Cytotoxic T-lymphocyte target proteins and their major histocompatibility complex class I restriction in response to adenovirus vectors delivered to mouse liver. J. Virol. 72: 2945-2954.
21. Kajiwara, K., A. P. Byrnes, H. M. Charlton, M. J. Wood, and K. J. Wood. 1997. Immune responses to adenoviral vectors during gene transfer in the brain. Hum. Gene Ther. 8:253-265.
22. Kaplan, J. M., D. Armentano, T. E. Sparer, S. G. Wynn, P. A. Peterson, S. C. Wadsworth, K. K. Couture, S. E. Pennington, J. A. St. George, and L. R. Smith. 1997. Characterization of factors involved in modulating persistence of transgene expression from recombinant adenovirus in the mouse lung. Hum. Gene Ther. 8:45-56.
23. Kleinberger, T., and T. Shenk. 1993. Adenovirus E4orf4 protein binds to protein phosphatase 2A, and the complex down regulates E1A-enhanced junB transcription. J. Virol. 67:7555-7560.
24. Kochaneck, S., P. R. Clemens, K. Mitani, H.-H. Chen, S. Chan, and C. T. Caskey. 1996. A new adenoviral vector: replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and β-galactosidase. Proc. Natl. Acad. Sci. USA 93:5731-5736.
25. Lapcevich, C., Q. Kang, and M. Gorziglia. Unpublished results.
26. Leppard, K. N. 1997. E4 gene function in adenovirus, adenovirus vector and adeno-associated virus infections. J. Gen. Virol. 78:2131-2138.
27. Lieber, A., C.-Y. He, I. Kirillova, and M. A. Kay. 1996. Recombinant adenoviruses with large deletions generated by Cre-mediated excision exhibit different biological properties compared with first-generation vectors in vitro and in vivo. J. Virol. 70:8944-8960.
28. Lusky, M., M. Christ, K. Rittner, A. Dieterle, D. Dreyer, B. Mourot, H. Schultz, F. Stoeckel, A. Pavarani, and M. Mehtali. 1998. In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2a, or E1/E4 deleted. J. Virol. 72:2022-2032.
29. Maizel, J. V., D. O. White, and M. D. Scarff. 1968. The polypeptides of adenovirus. II. Soluble proteins, cores, top components and structure of the virion. Virology 36:126-136.
30. Mitani, K., F. L. Graham, C. T. Caskey, and S. Kochanek. 1995. Rescue, propagation, and partial purification of a helper virus-dependent adenovirus vector. Proc. Natl. Acad. Sci. USA 92:3854-3858.
31. Moray, M. A., M. Gu, S. Motzel, J. Zhao, J. Lin, Q. Su, H. Allens, L. Franlin, R. J. Parks, F. L. Graham, S. Kochaneck, A. J. Bett, and C. T. Caskey. 1998. An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene. Proc. Natl. Acad. Sci. USA 95:7866-7871.
32. Nevels, M., S. Rubenwolf, T. Spruss, H. Wolf; and T. Dobner. 1997. The adenovirus E4orf6 protein can promote E1A/E1β-induced focus formation by interfering with p53 tumor suppressor function. Proc. Natl. Acad. Sci. USA 94:1206-1211.
33. Nevins, J. R. 1991. Utilization of cellular transcription factors for adenovirus-induced transcription. Virus Res. 20:1-10.
34. Schiedner, G., N. Morral, R. J. Parks, Y. Wu, S. C. Koopmans, C. Langston, F. L. Graham, A. L. Beaudet, and S. Kochanek. 1998. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat. Genet. 18:180-183.
35. Smith, T. A. G., M. G. Mehaffey, D. B. Kayda, J. M. Saunders, S. Yei, B. C. Trapnell, A. McClelland, and M. Kaleko. 1993. Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice. Nat. Genet. 5:397-402.
36. Trapnell, B. C. 1993. Adenoviral vectors for gene transfer. Adv. Drug Delivery Rev. 12:185-199.
37. Trapnell, B. C., and M. Gorziglia. 1994. Gene therapy using adenoviral vectors. Curr. Opin. Biotechnol. 5:617-625.
38. Tripathy, S. K., H. B. Black, E. Goldwasser, and J. M. Leiden. 1996. Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nat. Med. 2: 545-550.
39. Vrati, S., E. S. Macavoy, Z. Z. Xu, C. Smole, D. B. Boyle, and G. W. Both. 1996. Construction and transfection of ovine adenovirus genomic clones to rescue modified viruses. Virology 210:200-203.
40. Wang, Q., C. Greenburg, D. Bunch, D. Farson, and M. H. Finer. 1997. Persistent transgene expression in mouse liver following in vivo gene transfer with dlE1/dlE4 adenovirus vectors. Gene Ther. 4:393-400.
41. Yang, Y., H. C. J. Ertl, and J. M. Wilson. 1994. MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with El-deleted recombinant adenoviruses. Immunity 1:433-442.
42. Yang, Y., F. A. Nunes, K. Berencsi, E. E. Furth, E. Gonczol, J. F. Engelhardt, and J. M. Wilson. 1994. Cellular immunity to viral antigens limits El-deleted adenoviruses for gene therapy. Proc. Natl. Acad. Sci. USA 91:4407-4411.
43. Yang, Y., F. A. Nunes, K. Berencsi, E. Gonczol, J. F. Engelhardt, and J. M. Wilson. 1994. Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nat. Genet. 7:362-369.
44. Yang, Y., Q. Li, H. J. C. Ertl, and J. M. Wilson. 1995. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenovirus. J. Virol. 69:2004-2015.
45. Yei, S., N. Mittereder, S. Wert, J. A. Whitsett, R. W. Wilmott, and B. C. Trapnell. 1994. In vivo evaluation of the safety of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator cDNA to the lung. Hum. Gene Ther. 5:731-744.